Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Apr 27, 2014; 6(4): 178-187
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.178
Update on inflammatory bowel disease in patients with primary sclerosing cholangitis
Christos Tsaitas, Anysia Semertzidou, Emmanouil Sinakos
Christos Tsaitas, Anysia Semertzidou, Emmanouil Sinakos, 4th Internal Medicine Unit, University Hospital of Thessaloniki, Thessaloniki 54642, Greece
Author contributions: Tsaitas C and Semertzidou A drafted the manuscript; Sinakos E revised the manuscript critically for important intellectual content.
Correspondence to: Emmanouil Sinakos, MD, 4th Internal Medicine Unit, University Hospital of Thessaloniki, 11A, Perdika Str, Pilea, 55535, Thessaloniki 54642, Greece.
Telephone: +30-2310-950680 Fax: +30-2310-950680
Received: October 28, 2013
Revised: March 5, 2014
Accepted: March 13, 2014
Published online: April 27, 2014
Core Tip

Core tip: Combination of primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) has recently arisen as a challenging research field. Recent data highlight the specific clinical and genetic traits that differentiate PSC-IBD from the two diseases individually. We reviewed the literature on colorectal neoplastic susceptibility in this subset of patients and the underlying pathogenetic mechanisms. We also emphasize the technological advances that have provided novel diagnostic tools for more accurate detection of dysplastic lesions. Finally, we present current guidelines on follow-up as well as all evidence available as to whether ursodeoxycholic acid should be used prophylactically against colorectal cancer.